The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome

Schizophrenia Research

Volumn 80, Issue 1, 2005, Pages 9-18

  Meyer, Jonathan M ^a,b   Nasrallah, Henry A ^c   McEvoy, Joseph P ^d,e   Goff, Donald C ^f,g   Davis, Sonia M ^h   Chakos, Miranda ⁱ   Patel, Jayendra K ^j   Keefe, Richard S E ^k   Stroup, T Scott ^l   Lieberman, Jeffrey A ^m  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e John Umstead Hospital   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Freedom Trail Clinic   (United States)

^h IQVIA   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

Comorbidity; Health; Metabolic syndrome; Rating; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ETHNOLOGY; FEMALE; HEALTH PROGRAM; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL CAPACITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; RATING SCALE; RELIABILITY; SCHIZOPHRENIA; SELF CONCEPT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; ANTHROPOMETRY; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; PREVALENCE; SCHIZOPHRENIA; TRIGLYCERIDES;

EID: 27744456032     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.07.015     Document Type: Article

References (59)

1. C.M. Alexander, P.B. Landsman, S.M. Teutsch, S.M. Haffner, H. Third National, S. Nutrition Examination, and P. National Cholesterol Education NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older Diabetes 52 2003 1210 1214
2. P. Allebeck Schizophrenia: a life-shortening disease Schizophrenia Bulletin 15 1989 81 89
3. D.B. Allison, and D.E. Casey Antipsychotic-induced weight gain: a review of the literature Journal of Clinical Psychiatry 62 2001 22 31
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes Journal of Clinical Psychiatry 65 2004 267 272
5. R. Basu, J.S. Brar, K.N.R. Chengappa, V. John, H. Parepally, S. Gershon, P. Schlicht, and D. Kupfer The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype Bipolar Disorders 6 2004 314 318
6. S. Brown Excess mortality of schizophrenia. A meta-analysis British Journal of Psychiatry 171 1997 502 508
7. S. Brown, H. Inskip, and B. Barraclough Causes of the excess mortality of schizophrenia British Journal of Psychiatry 177 2000 212 217
8. E.S. Brown, F.P. Varghese, and B.S. McEwen Association of depression with medical illness: does cortisol play a role? Biological Psychiatry 55 2004 1 9
9. C. Bushe, and R. Holt Prevalence of diabetes and glucose intolerance in patients with schizophrenia British Journal of Psychiatry 184 2004 67 71
10. G.P. Chrousos The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 24 2000 S50 S55
11. T. Cohn, D. Prud'homme, D. Streiner, H. Kameh, and G. Remington Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 49 2004 753 760
12. J. Cradock-O'Leary, A.S. Young, E.M. Yano, M. Wang, and M.L. Lee Use of general medical services by VA patients with psychiatric disorders Psychiatric Services 53 2002 874 878
13. L. Dixon, L. Postrado, J. Delahanty, P.J. Fischer, and A. Lehman The association of medical comorbidity in schizophrenia with poor physical and mental health Journal of Nervous and Mental Disease 187 1999 496 502
14. L. Dixon, P. Weiden, J. Delahanty, R. Goldberg, L. Postrado, A. Lucksted, and A. Lehman Prevalence and correlates of diabetes in national schizophrenia samples Schizophrenia Bulletin 26 2000 903 912
15. B.G. Druss, D.W. Bradford, R.A. Rosenheck, M.J. Radford, and H.M. Krumholz Mental disorders and use of cardiovascular procedures after myocardial infarction [see comments] JAMA 283 2000 506 511
16. B.G. Druss, W.D. Bradford, R.A. Rosenheck, M.J. Radford, and H.M. Krumholz Quality of medical care and excess mortality in older patients with mental disorders Archives of General Psychiatry 58 2001 565 572
17. I. Elman, C.M. Adler, A.K. Malhotra, C. Bir, D. Pickar, and A. Breier Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia American Journal of Psychiatry 155 1998 979 981
18. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
19. E.S. Ford, W.H. Giles, and W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey JAMA 287 2002 356 359
20. E.S. Ford, W.H. Giles, and A.H. Mokdad Increasing prevalence of the metabolic syndrome among US adults Diabetes Care 27 2004 2444 2449
21. L.S. Goldman Medical illness in patients with schizophrenia Journal of Clinical Psychiatry 60 1999 10 15
22. S.M. Grundy, B. Brewer, J.I. Cleeman, S.C. Smith, and C. Lenfant Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438
23. T. Heiskanen, L. Niskanen, R. Lyytikainen, P.I. Saarinen, and J. Hintikka Metabolic syndrome in patients with schizophrenia Journal of Clinical Psychiatry 64 2003 575 579
24. Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
25. B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M.R. Taskinen, and L. Groop Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683 689
26. H. Jin, J.M. Meyer, and D.V. Jeste Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases Annals of Clinical Psychiatry 14 2002 59 64
27. H. Jin, J.M. Meyer, and D.V. Jeste Atypical antipsychotics and glucose dysregulation: a systematic review Schizophrenia Research 71 2004 195 212
28. D.R. Jones, C. Macias, P.J. Barreira, W.H. Fisher, W.A. Hargreaves, and C.M. Harding Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness Psychatric Services 55 2004 1250 1257
29. Y. Kaneda, A. Fujii, and T. Ohmori The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics Progress in Neuro-Psychopharmacology and Biological Psychiatry 26 2002 935 938
30. L.S. Kinder, M.R. Carnethon, L.P. Palaniappan, A.C. King, and S.P. Fortmann Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey Psychosomatic Medicine 66 2004 316 322
31. T.J. Lambert, D. Velakoulis, and C. Pantelis Medical comorbidity in schizophrenia Medical Journal of Australia 178 2003 S67 S70
32. P.D. Le Fevre Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? Scottish Medical Journal 46 2001 11 13
33. Loh, C., Meyer, J.M., Leckband, S.G., in press. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry.
34. C.G. Lyketsos, G. Dunn, M.J. Kaminsky, and W.R. Breakey Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay Psychosomatics 43 2002 24 30
35. S. Malik, and M.L. Kashyap Niacin, lipids, and heart disease Current Cardiology Reports 5 2003 470 476
36. S.R. Marder, S.M. Essock, A.L. Miller, R.W. Buchanan, D.E. Casey, J.M. Davis, J.M. Kane, J.A. Lieberman, N.R. Schooler, N. Covell, S. Stroup, E.M. Weissman, D.A. Wirshing, C.S. Hall, L. Pogach, X. Pi-Sunyer, J.T. Bigger Jr., A. Friedman, D. Kleinberg, S.J. Yevich, B. Davis, and S. Shon Physical health monitoring of patients with schizophrenia American Journal of Psychiatry 161 2004 1334 1349
37. K.I. Melkersson, M.L. Dahl, and A.L. Hulting Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism Psychopharmacology 175 2004 1 6
38. J.M. Meyer Awareness of obesity and weight issues among chronically mentally ill inpatients: a pilot study Annals of Clinical Psychiatry 14 2002 39 45
39. J.M. Meyer, and C.E. Koro The effects of antipsychotic therapy on serum lipids: a comprehensive review Schizophrenia Research 70 2004 1 17
40. J.M. Meyer H.A. Nasrallah Medical Illness and Schizophrenia 2003 American Psychiatric Press, Inc. Washington, D.C.
41. P.B. Mortensen, and K. Juel Mortality and causes of death in schizophrenic patients in Denmark Acta Psychiatrica Scandinavica 81 1990 372 377
42. P.B. Mortensen, and K. Juel Mortality and causes of death in first admitted schizophrenic patients British Journal of Psychiatry 163 1993 183 189
43. S.C. Newman, and R.C. Bland Mortality in a cohort of patients with schizophrenia: a record linkage study Canadian Journal of Psychiatry-Revue Canadienne de Psychiatrie 36 1991 239 245
44. U. Osby, N. Correia, L. Brandt, A. Ekbom, and P. Sparen Mortality and causes of death in schizophrenia in Stockholm county, Sweden Schizophrenia Research 45 2000 21 28
45. U. Osby, N. Correia, L. Brandt, A. Ekbom, and P. Sparen Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study BMJ 321 2000 483 484
46. Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, and S.B. Heymsfield The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994 [see comment] Archives of Internal Medicine 163 2003 427 436
47. K. Raikkonen, K.A. Matthews, and L.H. Kuller The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism, Clinical and Experimental 51 2002 1573 1577
48. D.G. Robinson, M.G. Woerner, J.M. Alvir, R.M. Bilder, G.A. Hinrichsen, and J.A. Lieberman Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder Schizophrenia Research 57 2002 209 219
49. R. Rosmond The glucocorticoid receptor gene and its association to metabolic syndrome Obesity Research 10 2002 1078 1086
50. M.C. Ryan, and J.H. Thakore Physical consequences of schizophrenia and its treatment: the metabolic syndrome Life Sciences 71 2002 239 257
51. M.C. Ryan, P. Collins, and J.H. Thakore Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia American Journal of Psychiatry 160 2003 284 289
52. J.C. Simpson, and M.T. Tsuang Mortality among patients with schizophrenia Schizophrenia Bulletin 22 1996 485 499
53. M.N. Starkman, B. Giordani, S.S. Gebarski, S. Berent, M.A. Schork, and D.E. Schteingart Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease Biological Psychiatry 46 1999 1595 1602
54. T.S. Stroup, J.P. McEvoy, M.S. Swartz, M.J. Byerly, I.D. Glick, J.M. Canive, M.F. McGee, G.M. Simpson, M.C. Stevens, and J.A. Lieberman The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development Schizophrenia Bulletin 29 2003 15 31
55. M.S. Swartz, D.O. Perkins, T.S. Stroup, J.P. McEvoy, J.M. Nieri, and D.C. Haak Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial Schizophrenia Bulletin 29 2003 33 43
56. J.H. Thakore, J.N. Mann, I. Vlahos, A. Martin, and R. Reznek Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 26 2002 137 141
57. R.J. Troisi, C.C. Cowie, and M.I. Harris Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon JAMA 284 2000 3157 3159
58. UK HDL-C Consensus Group Role of fibrates in reducing coronary risk: a UK consensus Current Medical Research and Opinion 20 2004 241 247
59. P.J. Weiden, J.A. Mackell, and D. McDonnell Obesity as a risk factor for antipsychotic noncompliance Schizophrenia Research 66 2004 51 57